HoldsUp

Giselle Petzinger

Keck School of Medicine at the University of Southern California

Giselle Petzinger, MD, is a board-certified neurologist at the Keck School of Medicine at the University of Southern California who specializes in Parkinson's disease. Her research focuses on neuroplasticity and brain repair mechanisms in clinical and preclinical models of Parkinson's disease. Her published work investigates the effects of exercise and physical activity on motor and cognitive function, as well as neuroimaging markers such as perivascular space volume and structural network connectivity.

21 claims checked on air: 1 context 1 overstated 16 supported 3 unverified 1 flagged

What they said on air

0:05:06supportedmoderateDr. Giselle Petzinger on Exercise for Parkinson's Disease

Anxiety and depression can precede the onset of motor symptoms in Parkinson's disease by up to two years.

"In fact, we're now recognizing—there are a number of papers that have come out now years ago—that anxiety, depression may even predate motor symptoms by two years" (said at 0:05:06)

Substantial epidemiological and clinical evidence demonstrates that neuropsychiatric non-motor symptoms, particularly depression and anxiety, frequently precede the onset of classic motor symptoms and clinical diagnosis in Parkinson's disease. Prospective cohort studies and clinical criteria indicate that these symptoms can emerge several years (typically 2 to 10 years) prior to motor manifestations.

0:07:00unverifiedvery lowDr. Giselle Petzinger on Exercise for Parkinson's Disease

Approximately 40% of Parkinson's disease patients exhibit mild cognitive impairment at the time of diagnosis.

"The literature is sort of all over the place, but essentially they're reporting about 40% even upon diagnosis may already have some cognitive issues. Now, that's not the same thing as dementia. So this is called mild cognitive impairment" (said at 0:07:00)

No published record matching the claim that approximately 40% of patients exhibit mild cognitive impairment at the time of Parkinson's disease diagnosis was located; this does not prove the claim false.

0:08:44supportedmoderateDr. Giselle Petzinger on Exercise for Parkinson's Disease

At clinical manifestation of Parkinson's disease, patients have approximately 40 to 50% substantia nigra cell loss and 60 to 80% striatal dopamine loss.

"We think about it as actually about 40, let's say to 50%, cell loss, and 60 to 80% dopamine loss. So there's a bit of a disconnect between the amount of cell loss and dopamine depletion." (said at 0:08:44)

Neuropathological and neuroimaging studies consistently indicate that clinical motor symptoms in Parkinson's disease emerge following substantial pre-symptomatic degeneration, classically estimated at approximately 40% to 50% loss of substantia nigra dopaminergic neurons (with landmark postmortem stereological calculations identifying approximately 48% overall caudal substantia nigra neuronal loss at symptom onset) and a disproportionately greater 50% to 80% reduction in striatal/putaminal dopaminergic innervation and dopamine content.

0:10:42supportedlowDr. Giselle Petzinger on Exercise for Parkinson's Disease

Long-term depression (LTD) is the predominant form of synaptic plasticity thought to occur in the striatum during motor control.

"LTD is the predominant form that's thought to be occurring there in the striatum, particularly in motor control." (said at 0:10:42)

Electrophysiological and basal ganglia literature supports the assertion that long-term depression (LTD) at corticostriatal synapses has historically and mechanistically been considered the predominant form of synaptic plasticity underlying striatal function and motor control. Corticostriatal LTD relies on dopamine and endocannabinoid signaling to downregulate excitatory cortical input to striatal medium spiny neurons during motor learning, although bidirectional plasticity (including long-term potentiation, LTP) is also recognized to occur under specific conditions.

0:15:19overstatedhighDr. Giselle Petzinger on Exercise for Parkinson's Disease

Parkinson's disease affects approximately 1 in 100 people over the age of 50.

"the idea is that 1 in 100 over the age of 50 have Parkinson's disease" (said at 0:15:19)

A systematic review and meta-analysis of global epidemiological studies shows that Parkinson's disease (PD) prevalence increases markedly with age but does not reach 1 in 100 (1%) at age 50. For individuals aged 50–59 years, pooled prevalence is 107 per 100,000 (~0.1% or ~1 in 1,000). The 1% threshold (approximately 1,087 per 100,000) is reached in the 70–79 age group, with rates rising to ~1.9% in those over 80. Stating that 1 in 100 people over 50 have Parkinson's overstates the prevalence for individuals in their 50s and 60s by several-fold.

0:15:24supportedhighDr. Giselle Petzinger on Exercise for Parkinson's Disease

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease.

"Second leading, yeah, definitely the second right behind Alzheimer's." (said at 0:15:24)

Extensive epidemiological data and neurological literature confirm that Parkinson's disease is the second most common neurodegenerative disorder globally, surpassed only by Alzheimer's disease.

0:15:31supportedmoderateDr. Giselle Petzinger on Exercise for Parkinson's Disease

Strong genetic contributions to Parkinson's disease are predominantly found in young-onset cases occurring under the age of 35.

"So in general, we think that genetics play—certainly the genetic risk factors, but in terms of strong genetic contributions, most of that data seems to be in young-onset. By young-onset, I mean younger than 35, for example." (said at 0:15:31)

Published genomic and clinical studies support the claim that strong monogenic contributions to Parkinson's disease (such as pathogenic variants in PRKN, PINK1, and DJ-1) are significantly enriched in young-onset cases, especially in individuals with symptom onset at or below 35 to 40 years of age. While late-onset Parkinson's disease is predominantly idiopathic or associated with lower-penetrance genetic risk factors, the diagnostic yield for causative monogenic variants rises substantially in individuals presenting before age 35.

0:16:21supportedmoderateDr. Giselle Petzinger on Exercise for Parkinson's Disease

Epidemiological studies demonstrate a higher risk of Parkinson's disease in rural settings compared to urban settings.

"some of that epidemiological data, which is the idea that there's been some higher risk in rural settings than in urban settings, the idea that environment does seem to play a role." (said at 0:16:21)

Multiple systematic reviews and meta-analyses of epidemiological studies demonstrate an increased risk of Parkinson's disease associated with rural living compared to non-rural settings. A meta-analysis by Priyadarshi et al. found a combined odds ratio of 1.56 (95% CI 1.18–2.07) for rural residence overall and 2.17 (95% CI 1.54–3.06) for US-based studies. A subsequent systematic review and meta-analysis by Noyce et al. confirmed a statistically significant positive association between rural living and Parkinson's disease diagnosis, alongside related environmental exposures such as farming and pesticide use.

0:18:54supportedmoderateDr. Giselle Petzinger on Exercise for Parkinson's Disease

In the 1980s, intravenous drug users in the Bay Area developed acute parkinsonism after injecting synthetic heroin contaminated with the protoxin MPTP.

"in the 1980s there was sort of an outbreak, if you will, of Parkinson's. And what was so unusual about it is that these particular individuals—and there were about eight individuals, let's say, that presented around the Bay Area in various emergency rooms—had essentially developed Parkinson's features overnight... they had been heroin users and that they had gotten some access to some synthesized heroin, essentially, that had been tainted with this protoxin, if you will." (said at 0:18:54)

The claim is supported by landmark published case studies. In July 1982, intravenous drug users in Northern California (the San Francisco Bay Area) rapidly developed severe, acute parkinsonism after injecting a synthetic heroin substitute (a meperidine analogue) contaminated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxic protoxin that selectively damages dopaminergic neurons in the substantia nigra.

0:19:26supportedhighDr. Giselle Petzinger on Exercise for Parkinson's Disease

MPTP is delivered to the brain and converted into the neurotoxin MPP+, which selectively destroys dopamine cells.

"MPTP is sort of a protoxin; it gets delivered to the brain, and there it gets converted to MPP+... when they injected it directly into their vein, they essentially blew out their—so it killed dopamine cells." (said at 0:19:26)

The speaker's statement accurately summarizes the established mechanism and clinical history of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. MPTP functions as a lipophilic protoxin that crosses the blood-brain barrier, where it is metabolized (primarily by glial monoamine oxidase B) into 1-methyl-4-phenylpyridinium (MPP+). MPP+ is selectively taken up by the dopamine transporter into dopaminergic neurons, leading to mitochondrial complex I inhibition, oxidative damage, and selective degeneration of dopaminergic neurons in the substantia nigra. This mechanism was famously identified in humans who intravenously injected synthetic heroin contaminated with MPTP and developed acute parkinsonism.

0:26:32supportedmoderateDr. Giselle Petzinger on Exercise for Parkinson's Disease

In the Nun Study, participants maintained cognitive function and high cognitive capacity despite postmortem findings of significant Alzheimer's amyloid pathology.

"I give the example of Alzheimer's, right? And and amyloid is an example where people have looked at, for example, the Nun Study, where nuns had basically given writing samples over time and showing, you know, their their level of education and cognitive capacity, if you will, um, and yet having a fairly significant amyloid load." (said at 0:26:32)

The claim accurately describes key findings from the Nun Study (a longitudinal study of aging in Catholic nuns who provided early-life autobiographical writing samples). Researchers found that some participants maintained normal cognitive function late in life despite postmortem brain autopsies demonstrating significant Alzheimer's neuropathology, including high amyloid plaque and neurofibrillary tangle burdens (termed asymptomatic Alzheimer's disease or ASYMAD). Early-life linguistic ability (idea density evaluated from early autobiographical writings) and education correlated with preserved cognitive capacity in the presence of AD pathology.

0:30:04unverifiedvery lowDr. Giselle Petzinger on Exercise for Parkinson's Disease

In Parkinson's disease, approximately 40% of cells are lost before functional impairment becomes clinically evident.

"Parkinson's disease, remember, I mean, that think about that model itself. There's a threshold there. I mean, I've lost, you know, 40% of cells before I I show any functional impairment, right?" (said at 0:30:04)

No published record matching the claim that approximately 40% of cells are lost before functional impairment becomes clinically evident in Parkinson's disease was located; this does not prove the claim false.

0:38:45supportedvery lowDr. Giselle Petzinger on Exercise for Parkinson's Disease

In rodent models of Parkinson's disease, animals running on a motorized wheel with missing spokes (skillful exercise) showed significantly higher blood flow in top-down cognitive circuits compared to animals on a regular wheel matched for speed.

"And some of the work that a colleague, Dr. Holschneider here at USC, has shown is, uh, certainly in the animal models that we've been doing, looking or trying to separate out or tease apart these different mechanisms, where one group of rodents with Parkinson's have gone through a type of exercise practice more skillful, meaning they're on a motorized wheel with spokes removed. Animals definitely need to pay more attention versus a group of animals, parkinsonian, where there aren't spokes to move, so it's nice and smooth, they don't have to think as much about what they're doing. Same matched for speed. The animals that have the spokes removed have blood flow in top-down circuit cognitive domains much more so than animals that don't." (said at 0:38:45)

The claim accurately summarizes published research from Dr. Holschneider and colleagues evaluating skilled versus simple exercise in rodent models of Parkinson's disease. In a 6-hydroxydopamine (6-OHDA) bilateral striatal lesion rat model of Parkinson's, animals trained on a motorized complex running wheel with irregularly spaced rungs (skilled aerobic exercise) demonstrated significantly greater increases in regional cerebral blood flow in the prelimbic prefrontal cortex and enhanced prefrontal-motor functional connectivity compared to rats trained on a standard, regular running wheel matched for speed. Because the findings are derived exclusively from preclinical rodent experiments, the overall certainty of the evidence is very low.

0:48:12supportedhighDr. Giselle Petzinger on Exercise for Parkinson's Disease

Hypoxia-inducible factor 1-alpha (HIF-1alpha) is upregulated in the context of exercise.

"hypoxia-inducible factor, HIF-1 HIF alpha is one example of a transcription factor that is known to be upreg—upregulated in the context of hypoxia, and now our cells and other groups have reported some upregulation, that is the context of exercise." (said at 0:48:12)

Hypoxia-inducible factor 1-alpha (HIF-1α) is well-established as being upregulated during hypoxia and is also upregulated in response to physical exercise. A 2025 systematic review and meta-analysis of 21 human studies examining exercised skeletal muscle confirmed that both HIF-1α mRNA and protein levels are significantly elevated following dynamic, high-intensity, and resistance exercise.

1:01:02supportedhighDr. Giselle Petzinger on Exercise for Parkinson's Disease

Cognitive impairment is common in Parkinson's disease and is a major contributor to long-term disability.

"And again, we talked about the idea that cognitive impairment is common in Parkinson's disease, probably is finally the biggest disability over time." (said at 1:01:02)

Extensive clinical cohort evidence and expert consensus confirm that cognitive impairment is highly prevalent in Parkinson's disease and represents one of the leading contributors to long-term functional disability, loss of independence, and caregiver burden as the disease progresses.

1:03:31supportedhighDr. Giselle Petzinger on Exercise for Parkinson's Disease

There is no clinical data showing that exercise stops disease progression or cures Parkinson's disease.

"One of the things I have to say, though, that I always try to make clear to people is, one, there's no data that it stops disease. So that's the one thing: it's never shown that it cures Parkinson's." (said at 1:03:31)

The speaker's statement is accurate. While extensive clinical trial and epidemiological evidence demonstrates that physical exercise improves motor symptoms, functional mobility, and quality of life in people with Parkinson's disease, there is currently no clinical evidence showing that exercise cures the disease or definitively stops underlying neurodegenerative progression. Clinical trials and reviews note that exercise offers symptomatic benefits and putative neuroprotective mechanisms in preclinical models, but proving disease-modifying or curative effects in humans remains an unproven goal.

1:05:17supportedlowDr. Giselle Petzinger on Exercise for Parkinson's Disease

Dopamine is required for synapse formation and synaptic plasticity, and dopamine depletion drives the loss of neural connections in Parkinson's disease.

"Because Parkinson's disease, as I said, causes obviously dopamine depletion with circuit changes, but dopamine depletion is driving some of these loss of connections. We need dopamine back because dopamine is what enables synapses to form as well, along with practice" (said at 1:05:17)

The claim is supported by neurobiological and preclinical evidence. In Parkinson's disease and animal models of dopamine denervation, the progressive loss of nigrostriatal dopamine leads to dendritic pruning and the loss of dendritic spines (axospinous synapses) on striatal medium spiny neurons. Dopamine signaling is a key modulator of striatal synaptic plasticity (such as long-term potentiation and depression) and structural spine remodeling, with dopamine restoration shown to support synaptic remodeling and reversal of morphological spine loss. Because evidence regarding structural spine dynamics and plastic adaptations derives primarily from post-mortem tissue and animal models, certainty is low.

1:07:50supportedhighDr. Giselle Petzinger on Exercise for Parkinson's Disease

In Parkinson's disease progression, surviving dopaminergic neurons lose the capacity to properly store dopamine, contributing to the need for more frequent levodopa dosing.

"One is that because those cells are not storing it as well, you're having to dose more frequently, so that's a cell dysfunction problem." (said at 1:07:50)

The statement accurately describes a fundamental pathophysiological mechanism in Parkinson's disease progression. In early Parkinson's disease, surviving nigrostriatal dopaminergic terminals can convert exogenous levodopa to dopamine, store it in synaptic vesicles, and release it in a regulated physiological manner. As neurodegeneration progresses and presynaptic terminal density declines, striatal dopamine buffering and storage capacity are lost. Consequently, synaptic dopamine levels become directly dependent on the short plasma half-life of levodopa (approximately 60–90 minutes), leading to 'wearing-off' motor fluctuations that necessitate more frequent levodopa administration or dosing adjustments.

1:08:20unverifiedvery lowDr. Giselle Petzinger on Exercise for Parkinson's Disease

Levodopa is less effective for cognitive dysfunction in Parkinson's disease than for motor symptoms because cognitive circuitry also involves acetylcholine, serotonin, and norepinephrine.

"And L-dopa does not do as much—it's not as effective for cognitive function. It has a role there, but it's one of many different chemicals: acetylcholine being another one, serotonin, norepinephrine being other ones." (said at 1:08:20)

No published record matching the claim that levodopa is less effective for cognitive dysfunction in Parkinson's disease because cognitive circuitry also involves acetylcholine, serotonin, and norepinephrine was located; this does not prove the claim false.

1:16:50supportedhighDr. Giselle Petzinger on Exercise for Parkinson's Disease

Patients with Parkinson's disease show elevated levels of pro-inflammatory cytokines such as TNF-alpha and IL-6.

"Yeah, so there's some data. Interestingly, there are hints here and there—it's again not as well worked out as, you know, MS, for example—but yeah, the idea that there is TNF-alpha, IL-6, so the idea that there may be higher pro-inflammatory cytokines." (said at 1:16:50)

A systematic review and meta-analysis of peripheral blood cytokine levels in patients with Parkinson's disease (PD) vs. healthy controls found significantly higher blood concentrations of pro-inflammatory cytokines, including TNF-alpha (Hedges g = 0.354, 95% CI 0.144–0.563, p = 0.001) and IL-6 (Hedges g = 0.325, 95% CI 0.007–0.643, p = 0.045) (Qin et al., 2016). Additionally, a meta-analysis of cerebrospinal fluid (CSF) biomarkers demonstrated significantly elevated levels of IL-6 in the CSF of patients with PD compared to controls (Wang et al., 2018).

1:18:00needs contextmoderateDr. Giselle Petzinger on Exercise for Parkinson's Disease

Most exercise clinical studies in Parkinson's disease utilize an intervention frequency of approximately three times per week for at least 30 minutes.

"Yeah, I mean, most of the studies are about three times a week, so I'd say about three times a week, minimally 30 minutes three times a week, and trying to make it as intense as possible, yeah." (said at 1:18:00)

Standard aerobic exercise recommendations derived from clinical trials in Parkinson's disease recommend a frequency of 3 times per week for 30 to 40 minutes per session at moderate-to-high intensity. However, across the broader literature of exercise interventions in Parkinson's disease (including modalities such as Tai Chi, dance, and community-based programs), trial protocols vary significantly, with many meta-analyses noting that twice-weekly sessions of 60 minutes are frequently utilized.

Fact-checked episodes

Publications